Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Net Margin (2017 - 2026)

Neurocrine Biosciences filings provide 15 years of Net Margin readings, the most recent being 19.08% for Q4 2025.

  • On a quarterly basis, Net Margin rose 266.0% to 19.08% in Q4 2025 year-over-year; TTM through Dec 2025 was 16.73%, a 224.0% increase, with the full-year FY2025 number at 16.73%, up 224.0% from a year prior.
  • Net Margin hit 19.08% in Q4 2025 for Neurocrine Biosciences, down from 26.36% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 28.67% in Q4 2023 to a low of 84.5% in Q2 2022.
  • Median Net Margin over the past 5 years was 15.14% (2025), compared with a mean of 8.0%.
  • Biggest five-year swings in Net Margin: plummeted -14268bps in 2021 and later surged 10560bps in 2023.
  • Neurocrine Biosciences' Net Margin stood at 2.34% in 2021, then surged by 1023bps to 21.6% in 2022, then skyrocketed by 33bps to 28.67% in 2023, then plummeted by -43bps to 16.43% in 2024, then increased by 16bps to 19.08% in 2025.
  • The last three reported values for Net Margin were 19.08% (Q4 2025), 26.36% (Q3 2025), and 15.64% (Q2 2025) per Business Quant data.